NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $122.74 -3.15 (-2.50%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeneDx alerts:Sign Up Key Stats Today's Range$122.75▼$126.1050-Day Range$77.87▼$132.5452-Week Range$35.88▼$136.00Volume48,377 shsAverage Volume1.02 million shsMarket Capitalization$3.53 billionP/E Ratio2,462.56Dividend YieldN/APrice Target$104.13Consensus RatingModerate Buy Company Overview GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting. Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards. GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.AI Generated. May Contain Errors. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 52% of companies evaluated by MarketBeat, and ranked 671st out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Downside RiskGeneDx has a consensus price target of $104.13, representing about 15.6% downside from its current price of $123.31.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth115.46% Earnings GrowthEarnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is 2,458.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 281.01.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is 2,458.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 74.86.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 14.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.42% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in GeneDx has recently decreased by 3.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.42% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in GeneDx has recently decreased by 3.71%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.12 News SentimentGeneDx has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for GeneDx this week, compared to 12 articles on an average week.Search Interest11 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,551,904.00 in company stock.Percentage Held by Insiders29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WGS Stock News HeadlinesGeneDx (NASDAQ:WGS) Director Sells $60,450,000.00 in StockAugust 23, 2025 | insidertrades.comAssessing GeneDx Holdings: Insights From 5 Financial Analysts3 hours ago | benzinga.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 12 at 2:00 AM | Paradigm Press (Ad)GeneDx price target raised to $140 from $120 at Piper SandlerSeptember 11 at 11:45 AM | msn.comGeneDx Holdings Corp. (NASDAQ:WGS) Receives $101.63 Average Price Target from AnalystsSeptember 9 at 2:29 AM | americanbankingnews.comGeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comGeneDx (WGS): Valuation in Focus Following Securities Investigation Triggered by Fraud AllegationsSeptember 7, 2025 | finance.yahoo.comZoomInfo, International Money Express, and More Stocks See Action From Activist InvestorsSeptember 5, 2025 | msn.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS stock has increased by 60.4% and is now trading at $123.3050. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) issued its quarterly earnings results on Tuesday, July, 29th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to analyst estimates of $86 million. GeneDx had a net margin of 0.39% and a trailing twelve-month return on equity of 16.51%. Read the conference call transcript. When did GeneDx's stock split? GeneDx's stock reverse split before market open on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? GeneDx's top institutional shareholders include William Blair Investment Management LLC (5.72%), Westfield Capital Management Co. LP (2.05%), Zweig DiMenna Associates LLC (2.05%) and Invesco Ltd. (1.93%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Karen Ann White, Kevin Feeley and Katherine Stueland. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings7/29/2025Today9/12/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Price Target for GeneDx$104.13 High Price Target$140.00 Low Price Target$80.00 Potential Upside/Downside-17.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.05 Trailing P/E Ratio2,517.80 Forward P/E Ratio129.78 P/E GrowthN/ANet Income-$52.29 million Net Margins0.39% Pretax Margin0.42% Return on Equity16.51% Return on Assets9.35% Debt Debt-to-Equity Ratio0.19 Current Ratio2.87 Quick Ratio2.70 Sales & Book Value Annual Sales$305.45 million Price / Sales11.84 Cash Flow$1.05 per share Price / Cash Flow120.39 Book Value$8.75 per share Price / Book14.39Miscellaneous Outstanding Shares28,730,000Free Float20,223,000Market Cap$3.62 billion OptionableOptionable Beta2.04 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:WGS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.